Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

OLEORESIN PAPRIKA

NFPA

PRODUCT USE

Food flavouring, colouring. Obtained by solvent extraction of paprika, which consists of
the ground fruit pods, with or without the seeds, of Capsicum annuum L and contains the
major flavouring and colouring principles of this spice; the major flavouring principle is
capsaicin; the major colouring principles are capsanthin and capsorubin; a wide variety of
other coloured compounds are known to be present. Only the following solvents may be used:
trichloroethylene, acetone, propan- 2- ol, methanol, ethanol, hexane. The solvent is
subsequently removed.

SYNONYMS

"Paprica extract", "Capsicum annum L. convar. grossum (L.) Terpo, extract", Solanaceae

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Accidental ingestion of the material may be damaging to the health of the individual.  Retinoid poisoning, as characterised by Vitamin A intoxication, may occur at high doses and is characterised by sedation, headache, irritability, papilloedema (oedema of the optic disk), and a generalised peeling of the skin. Although vitamin A is useful in preventing and treating chemical sensitivity, many chemically sensitive individuals, especially those who exhibit formaldehyde sensitivity, cannot tolerate it following oral administration.  Retinoids are frequently produced, in the organism, as a result of carotenoid metabolism.  Retinoids such as etretinate and isotretinoin, taken in therapeutic doses, may produce dryness of the mucous membranes, sometimes with erosion, involving the lips (cheilitis), mouth, conjunctiva (sometimes causing conjunctivitis), and nasal mucosa and epistaxis (rarely causing epistaxis). Other symptoms may include flare-up of acne, peeling of the palms, soles and fingertips, rhinorrhoea, nosebleed, gingival bleeding, nail fragility, easy sunburning, fever and mild headache. Ocular defects may include problems with night vision, and alterations in colour perception. Musculoskeletal effects include aching joints and backache. Neurological symptoms include fatigue, minor depression, and insomnia. Decreased libido and menstrual irregularities have been reported in etretinate therapies. Liver and kidney dysfunction has been suggested after abnormal laboratory tests and following the appearance of calcified tendons and ligaments in the ankles, pelvis, and knees; hepatitis has been reported in a significant number of patients (1.5%). Dryness of the skin may result in scaling, thinning, pruritus, exfoliation, and erythema. Thinning of the hair or alopecia may occur by the fourth week of etretinate treatment. Skeletal hyperostosis, benign intracranial hypertension, musculoskeletal pain, gastrointestinal effects and paronychia have also occurred. Serum levels of hepatic enzymes and triglyceride concentrations may be elevated.  Isotretinoin therapy has produced corneal opacities and premature epiphyseal closure. Such therapy has also been associated with skin infection and an inflammatory bowel syndrome.  

EYE

  Although the liquid is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.  

INHALED

  The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  

CHRONIC HEALTH EFFECTS

  Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.  Prolonged overdose of Vitamin A is associated with fatigue, irritability, loss of weight and appetite, mild fever, increased amounts of urine, enlarged liver and spleen, hair loss, bleeding lips, thickening of skin and yellow pigmentation. Bone and joint pain may occur, and growth may be permanently arrested in children. There may be birth defects and loss of bone mineral associated with carotenoids.